ArticleFrontiers in oncology2026
Multi-omics analysis identifies stemness-driven molecular subtypes, prognostic signature, epigenetic target APCDD1, and drug candidate Leflunomide in Wilms tumor.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilms tumor (WT), the most common pediatric renal malignancy, continues to present therapeutic challenges in refractory and relapsed patients. Stemness plays a crucial role in the development and progression of WT, yet the specific mechanisms involved are not yet fully understood. This study systematically investigated the molecular basis of stemness features in WT using multi-omics data and computational biology approaches. Single-cell RNA sequencing combined with the CytoTRACE algorithm revealed that the blastemal cells exhibited the highest stemness score, which correlated significantly with worse prognosis in WT patients. Consensus clustering based on prognostic stemness-related genes stratified WT samples into two distinct molecular subtypes (C1 and C2). The C1 subtype exhibited higher stemness, an immunosuppressive tumor microenvironment characterized by dysfunctional NK cells, and significantly worse clinical outcomes. We subsequently developed and validated a robust prognostic risk signature using Lasso-Cox regression. Mechanistic investigations uncovered that the tumor-suppressive effect of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.